Long-term side effects of HPV vaccine are unknown; 5.
The vaccine's enduring effectiveness is unknown and booster shots may be required; and 6.
On October 25, 2011, an advisory panel for the Centers for Disease Control and Prevention (CDC) voted to recommend that the vaccine should be given to boys ages 11–12.
The panel's recommendation is intended to prevent genital warts and anal cancers in males, and possibly prevent head and neck cancer (though the vaccine's effectiveness against head and neck cancers has not yet been proven).
In this editorial we address the controversies surrounding human papillomavirus (HPV) vaccine school-entry mandate legislation, but differentiate between the mandate debate and issues specific to the vaccine itself.
Our goal is not to take a stand in favor of or opposed to mandates, but rather to critically examine the issues.
As with females, the vaccine should be administered before infection with the HPV types covered by the vaccine occurs.
Vaccination before adolescence, therefore, makes it more likely that the recipient has not been exposed to HPV.
Opt-out provisions are inherently unfair to parents who oppose HPV vaccination; 4.In males, Gardasil may reduce their risk of genital warts and precancerous lesions caused by HPV.This reduction in precancerous lesions might be predicted to reduce the rates of penile and anal cancer in men.Since penile and anal cancers are much less common than cervical cancer, HPV vaccination of young men is likely to be much less cost-effective than for young women.From a public health point of view, vaccinating men as well as women decreases the virus pool within the population, but is only cost-effective if the uptake in the female population is extremely low. In early 2013 the two companies who sell the most common vaccines announced a price cut to less than per dose to poor countries, as opposed to 0 per dose in the US.Limited health care dollars should not be directed toward cervical cancer prevention; and 5.